No Data
Beijing Biostar Pharmaceuticals to Join Hang Seng Composite Index
Huahaotian Medicine-B (02563) issued a profit warning, anticipating an annual net loss of between 0.146 billion yuan and approximately 0.151 billion yuan.
Huahao Zhongtian Pharmaceutical-B (02563) announced that the group expects to record a net loss ranging between...
BIOSTAR PHARM-B: PROFIT ALERT - EXPECTED REDUCTION IN LOSS
Huahao Zhongtian Pharmaceutical-B (02563) has been included in the Hang Seng Composite Index and is expected to become a symbol for the Hong Kong Stock Connect.
According to a Research Report from CITIC SEC, China Haotian Medicine-B (02563) is likely to be included in the Hong Kong Stock Connect, as it meets a series of standards including Market Cap, liquidity, and listing time.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Beijing Biostar Pharmaceuticals Cancer Drug Receives US FDA Approval
